Interleukin-12 in Treating Patients With Multiple Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's blood cells to kill multiple myeloma cells. PURPOSE: Randomized phase II trial to compare the effectiveness of interleukin-12 given at different times in treating patients with multiple myeloma.

Key facts

Study ID

NCT00003149

Run by

Eastern Cooperative Oncology Group

People needed

40

Starts

1997-12-01

Expected to finish

2006-09-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Veterans Affairs Medical Center - Indianapolis (Roudebush) — Indianapolis, Indiana, United States
• CCOP - Iowa Oncology Research Association — Des Moines, Iowa, United States
• CCOP - Ochsner — New Orleans, Louisiana, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States
• Hunterdon Regional Cancer Center — Flemington, New Jersey, United States
• Morristown Memorial Hospital — Morristown, New Jersey, United States
• Overlook Hospital — Summit, New Jersey, United States
• University of Rochester Cancer Center — Rochester, New York, United States
• Hahnemann University Hospital — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.